Medilux Laboratories is an API manufacturer based in India. It holds 10 active US drug master files and 11 valid CEPs across a filed portfolio of 12 molecules. Its GMP standing is certified by US FDA and EMA. Its most recent recorded inspection, by US FDA, closed on 27 September 2024 as VAI. Customs aggregates show $5.6M of exports covering 160 molecules to 38 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Pithampur, India | 3005594847 |
| Molecule | Regulators | Docs |
|---|---|---|
| Torasemide | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
| Baclofen | EDQM, US FDA | 2 |
| Bisoprolol | EDQM, US FDA | 2 |
| Bumetanide | EDQM, US FDA | 2 |
| Buspirone | EDQM, US FDA | 2 |
| Dapsone | EDQM, US FDA | 2 |
| Deferasirox | EDQM, US FDA | 2 |
| Glimepiride | EDQM, US FDA | 2 |
| Hydroquinone | SFDA (Saudi Arabia) | 2 |
| Raloxifene | EDQM, US FDA | 2 |
| Trazodone | EDQM, US FDA | 2 |
| M-Cresol | EDQM | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | None | 1 |
| EMA | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $2.5M | 21 |
| 2025 | Not reported | $5.6M | 38 |
| 2024 | Not reported | $1.9M | 20 |
| 2023 | Not reported | $2.0M | 15 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Medilux Laboratories comes back tiered against every other supplier able to file there.
Start for free